How new cancer drugs can skip randomised trials

Research like the Zelboraf tests, which fine-tune treatments to patients’ genetic profiles, is fuelling a rethink of how new cancer drugs are tested

Powered by WPeMatico

Share
This entry was posted in Business. Bookmark the permalink.

Comments are closed.